Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
17.40
-0.26 (-1.47%)
At close: Sep 17, 2025, 4:00 PM EDT
17.74
+0.34 (1.95%)
After-hours: Sep 17, 2025, 4:30 PM EDT
Oculis Holding AG Revenue
Oculis Holding AG had revenue of 261.00K CHF in the quarter ending June 30, 2025, with 6.53% growth. This brings the company's revenue in the last twelve months to 764.00K, down -12.28% year-over-year. In the year 2024, Oculis Holding AG had annual revenue of 686.00K, down -22.31%.
Revenue (ttm)
764.00K CHF
Revenue Growth
-12.28%
P/S Ratio
947.93
Revenue / Employee
15,592 CHF
Employees
49
Market Cap
910.64M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 686.00K | -197.00K | -22.31% |
Dec 31, 2023 | 883.00K | -29.00K | -3.18% |
Dec 31, 2022 | 912.00K | -48.00K | -5.00% |
Dec 31, 2021 | 960.00K | -33.00K | -3.32% |
Dec 31, 2020 | 993.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
OCS News
- 8 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 13 days ago - Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025 - GlobeNewsWire
- 17 days ago - Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences - GlobeNewsWire
- 21 days ago - Oculis to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 24 days ago - Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D. - GlobeNewsWire
- 27 days ago - Oculis Reports Q2 2025 Financial Results and Provides Company Update - GlobeNewsWire
- 5 weeks ago - Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewsWire
- 5 weeks ago - Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewsWire